My colleagues on Mintels Consulting team, Vivienne Rudd and Alisha Taylor , have already done extensive work to understand and predict the impact on the beauty sector
J Neurochem 123(2):2938 Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, Koetse W, Purcaru O, Bennett B, Burkhardt H (2015) Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the certain double-blind, randomised, placebo-controlled trial
Supports healthy aging
This early phase, while uncomfortable, provides valuable information about your individual tolerance and helps establish the dietary adjustments that minimize ongoing discomfort
I decided to try this [CoolSculpting] first to see, and to my amazement, it worked
Remaining Challenges in ePA for GLP-1s While ePA greatly reduces friction, some challenges remain: Incomplete Payer Connectivity: Not every insurer will accept ePA for every drug/plan